Form 4: Fulgent Genetics' Chief Scientific Officer Gao Hanlin Reports Stock Transaction
SEC Form 4 Filing
Fulgent Genetics' Chief Scientific Officer, Gao Hanlin, reports the withholding of 1,154 common stock shares to cover tax obligations arising from vesting restricted stock units.
Summary
- On April 26, 2024, Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), had 1,154 shares of common stock withheld to satisfy tax obligations.
- The shares were withheld at a price of $20.1 per share.
- Following the transaction, Gao Hanlin directly owns 927,811 shares of Fulgent Genetics common stock.
- The tax obligations arose from the vesting of restricted stock units granted on November 7, 2022.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of a routine transaction related to executive compensation. It doesn't indicate positive or negative sentiment.
Industry Context
This is a routine disclosure related to executive compensation and tax obligations, common in publicly traded companies. It doesn't necessarily reflect a change in the company's outlook or strategy.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a standard tax withholding procedure.
Key Dates
| Date | Description |
|---|---|
| 11/07/2022 | Date of restricted stock units grant to Gao Hanlin. |
| 04/26/2024 | Date of the stock transaction (tax withholding). |
| 04/30/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.